Monday, July 11, 2022
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIAID), has launched a preliminary clinical trial to evaluate immunization against the virus. The experimental vaccine was developed in collaboration with Moderna, Inc., Cambridge, Massachusetts, and the NIAID Vaccine Research Center. It is based on the messenger RNA (MRI) platform — this technology is used in many approved CV-19 vaccines. NIAID is sponsoring a Level 1 clinical study at the NIH Clinic in Bethsaida, Maryland.
Nipah virus infection is a zonal disease that is transmitted between animals and humans. Fruit bats are the natural host of the virus. The first known Nipah epidemic Since 1999, outbreaks have occurred every year in Asia, mainly Bangladesh and India. From simple to severe disease, the virus can quickly spread from the symptoms of a respiratory infection to encephalitis (brain swelling) to coma or death. Between 40% and 75% of people infected with Nippah virus die. Although most cases are transmitted by animals, they can be transmitted from person to person. There is currently no vaccine or treatment for Nipah virus infection.
“Because the Nipa virus is relatively easily mutated, it causes disease in various mammals, can be transmitted from person to person and kills many of the infected people,” said Anthony S., director of NIAID. Fauci, MD: “The importance of immunization against Nippah virus is very important.”
NIAID’s Epidemiological readiness planPublished earlier this year, it has developed a framework for studying the potential potential epidemics and prioritizing research on parasites such as Nipah virus. This is the first clinical trial using a prototype pathogen approach after the publication of the plan.
The experimental mRNA-1215 Nipah virus vaccine is being tested in 40 clinical trials to assess the safety, tolerance and immunity of 40 healthy adults between the ages of 18 and 60 years. Specifically, four out of 10 participants will receive two doses of the test vaccine in the shoulder muscle every four or 12 weeks. Group One (10 participants) received two 25-micrograms (mcg) injections; The group received two 50-mcg injections; And group three each received two 100-mcg injections at a four-week interval. Vaccination rates for the fourth group of participants were determined based on a temporary analysis of the previous three groups. The fourth group received two injections at a 12-week interval. Participants will be evaluated at some point during the clinical examination and blood collection and will be followed up by clinical researchers within 52 weeks after their final vaccination.
For more information about the clinical trial, visit ClinicalTrials.gov using the study label NCT05398796.
NIAID conducts research and research in NIH, throughout the United States, and around the world — to study the causes of communicable diseases and to develop better methods to prevent, diagnose, and treat these diseases. News releases, fact sheets, and other NID-related materials are available at NIAID website.
About National Institutes of Health (NIH) ፡The National Medical Research Agency, which includes 27 institutes and centers, is part of the US Department of Health and Human Services. NIH is a major federal agency that conducts and supports basic, clinical and translational research, and is investigating the causes, treatments, and cures for both common and uncommon diseases. Visit for more information about NIH and its programs www.nih.gov.
NIH በመቀ Turning Discovery into Health®